OBJECTIVE: The aim of this study was to assess our clinical experience with
infliximab, a monoclonal antitumor necrosis factor antibody, following its
approval for treatment of refractory Crohn's disease (CD).
METHODS: We followed 100 consecutive patients with CD (53 women and 47 men;
mean age, 41 yr) who received a total of 233 infliximab (5 mg/kg) infusion
s. Adverse events were noted and clinical response assessed every 2 wk for
6 months after each infusion using the Harvey Bradshaw Index (HBI) for acti
ve disease, the Perianal Disease Activity Index (PDAI) for fistulous diseas
e, and steroid withdrawal rates for steroid-sparing efficacy.
RESULTS: Indications for therapy were active disease (n = 57), perianal fis
tulous disease (n = 33), and steroid dependency (n = 10). Significant infus
ion reactions occurred in 16 patients (6.9% of infusions) including anaphyl
actic shock in one patient. Fourteen patients experienced infectious advers
e events, 13 of whom were on concurrent steroids. Sixty percent of patients
with active disease experienced greater than or equal to 50% HBI reduction
at 2 wk; mean duration of response, 8.2 wk. Three of 26 first-time nonresp
onders with active disease (12%) responded to a second infusion. Sixty-nine
percent of patients with fistulous disease experienced >50% reduction in t
heir PDAI at 2 wk; mean duration of response, 10.9 wk. Four of 10 steroid-d
ependent patients (40%) discontinued steroid therapy, one of whom recommenc
ed steroid therapy at 24 wk.
CONCLUSIONS: Our clinical response rates mirror the efficacy reported in th
e controlled trials for active and fistulous disease. Steroid-sparing effic
acy was seen in 40% of steroid-dependent patients. Concurrent steroids did
not reduce the risk of significant infusion reactions (6.9%), but did incre
ase the risk of infections. (C) 2000 by Am. Cell. of Gastroenterology.